0 XP   0   0   0

Vivoryon Therapeutics NV










Financial Health of Vivoryon




Comparing to competitors in the Biotechnology industry




  Industry Rankings  


Richest
#783 / 1194

Total Sales
#1162 / 1194

Making Money
#520 / 1194

Working Efficiently
#619 / 1194

Vivoryon Therapeutics NV
Buy, Hold or Sell?

Should you buy, hold or sell Vivoryon?

I guess you are interested in Vivoryon Therapeutics NV. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

Let's analyse Vivoryon

Let's start. I'm going to help you getting a better view of Vivoryon Therapeutics NV. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

  1. Company's Financial Health
    A deep dive into the books. How are the numbers doing? Is Vivoryon Therapeutics NV even making a profit? Is the company skyrocketing? Or is it sinking like the Titanic. The trend is your friend.
  2. Market Valuation
    Finally, you now have an insight of how Vivoryon Therapeutics NV is doing in the market. If the company is worth buying. The latest step is to find out how other investors value Vivoryon Therapeutics NV. The closing price on 2022-11-28 was €9 per share. Is the company over- or underpriced?
  3. Key Performance Indicators
    A total overlook on how the company is doing. Based on the (trends in) the key performance indicators.
Vivoryon Therapeutics NV Daily Candlestick Chart

Summary

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

1.1. Profitability of Vivoryon Therapeutics NV.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Vivoryon earns for each €1 of revenue.

  • Above 10% is considered healthy but always compare Vivoryon to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that €0.00 for each €1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Vivoryon Therapeutics NV:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--223.6%+223.6%
TTM--281.7%+281.7%
YOY--344.8%+344.8%
5Y--450.1%+450.1%
10Y--541.0%+541.0%
1.1.2. Return on Assets

Shows how efficient Vivoryon is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Vivoryon to the Biotechnology industry mean.
  • -25.7% Return on Assets means that Vivoryon generated €-0.26 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Vivoryon Therapeutics NV:

  • The MRQ is -25.7%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -13.5%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-25.7%TTM-13.5%-12.1%
TTM-13.5%YOY-18.0%+4.5%
TTM-13.5%5Y-13.6%+0.1%
5Y-13.6%10Y-13.6%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-25.7%-9.9%-15.8%
TTM-13.5%-8.9%-4.6%
YOY-18.0%-9.3%-8.7%
5Y-13.6%-11.7%-1.9%
10Y-13.6%-12.7%-0.9%
1.1.3. Return on Equity

Shows how efficient Vivoryon is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Vivoryon to the Biotechnology industry mean.
  • -38.0% Return on Equity means Vivoryon generated €-0.38 for each €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Vivoryon Therapeutics NV:

  • The MRQ is -38.0%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -20.0%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-38.0%TTM-20.0%-18.0%
TTM-20.0%YOY-22.6%+2.5%
TTM-20.0%5Y-17.8%-2.2%
5Y-17.8%10Y-17.8%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-38.0%-12.0%-26.0%
TTM-20.0%-11.5%-8.5%
YOY-22.6%-10.8%-11.8%
5Y-17.8%-14.2%-3.6%
10Y-17.8%-15.2%-2.6%

1.2. Operating Efficiency of Vivoryon Therapeutics NV.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Vivoryon is operating .

  • Measures how much profit Vivoryon makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Vivoryon to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated €0.00  for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Vivoryon Therapeutics NV:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--207.3%+207.3%
TTM--271.0%+271.0%
YOY--325.9%+325.9%
5Y--454.0%+454.0%
10Y--537.1%+537.1%
1.2.2. Operating Ratio

Measures how efficient Vivoryon is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are €0.00 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of Vivoryon Therapeutics NV:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.871-2.871
TTM-3.504-3.504
YOY-3.604-3.604
5Y-5.132-5.132
10Y-6.371-6.371

1.3. Liquidity of Vivoryon Therapeutics NV.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Vivoryon is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 7.07 means the company has €7.07 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of Vivoryon Therapeutics NV:

  • The MRQ is 7.072. The company is very able to pay all its short-term debts. +2
  • The TTM is 5.675. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ7.072TTM5.675+1.397
TTM5.675YOY12.965-7.289
TTM5.6755Y22.108-16.433
5Y22.10810Y22.1080.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ7.0725.117+1.955
TTM5.6755.755-0.080
YOY12.9655.854+7.111
5Y22.1086.511+15.597
10Y22.1086.222+15.886
1.3.2. Quick Ratio

Measures if Vivoryon is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Vivoryon to the Biotechnology industry mean.
  • A Quick Ratio of 0.95 means the company can pay off €0.95 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Vivoryon Therapeutics NV:

  • The MRQ is 0.945. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.639. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.945TTM0.639+0.306
TTM0.639YOY0.125+0.514
TTM0.6395Y4.923-4.284
5Y4.92310Y4.9230.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.9454.284-3.339
TTM0.6394.664-4.025
YOY0.1254.787-4.662
5Y4.9235.218-0.295
10Y4.9235.182-0.259

1.4. Solvency of Vivoryon Therapeutics NV.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Vivoryon assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Vivoryon to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.32 means that Vivoryon assets are financed with 32.5% credit (debt) and the remaining percentage (100% - 32.5%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Vivoryon Therapeutics NV:

  • The MRQ is 0.325. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.326. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.325TTM0.326-0.001
TTM0.326YOY0.160+0.166
TTM0.3265Y0.196+0.130
5Y0.19610Y0.1960.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3250.278+0.047
TTM0.3260.277+0.049
YOY0.1600.306-0.146
5Y0.1960.367-0.171
10Y0.1960.403-0.207
1.4.2. Debt to Equity Ratio

Measures if Vivoryon is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Vivoryon to the Biotechnology industry mean.
  • A Debt to Equity ratio of 48.1% means that company has €0.48 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Vivoryon Therapeutics NV:

  • The MRQ is 0.481. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.483. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.481TTM0.483-0.002
TTM0.483YOY0.210+0.273
TTM0.4835Y0.273+0.210
5Y0.27310Y0.2730.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4810.315+0.166
TTM0.4830.317+0.166
YOY0.2100.319-0.109
5Y0.2730.403-0.130
10Y0.2730.462-0.189

2. Market Valuation of Vivoryon Therapeutics NV

2. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every €1 in earnings Vivoryon generates.

  • Above 15 is considered overpriced but always compare Vivoryon to the Biotechnology industry mean.
  • A PE ratio of -27.48 means the investor is paying €-27.48 for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Vivoryon Therapeutics NV:

  • The EOD is -31.543. Company is losing money. -2
  • The MRQ is -27.478. Company is losing money. -2
  • The TTM is -14.268. Company is losing money. -2
Trends
Current periodCompared to+/- 
EOD-31.543MRQ-27.478-4.066
MRQ-27.478TTM-14.268-13.209
TTM-14.268YOY-48.242+33.974
TTM-14.2685Y-31.438+17.170
5Y-31.43810Y-31.4380.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-31.543-8.986-22.557
MRQ-27.478-9.792-17.686
TTM-14.268-16.243+1.975
YOY-48.242-20.876-27.366
5Y-31.438-16.665-14.773
10Y-31.438-14.732-16.706

2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Vivoryon is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 10.44 means the investor is paying €10.44 for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of Vivoryon Therapeutics NV:

  • The EOD is 11.986. Seems overpriced? -1
  • The MRQ is 10.441. Seems overpriced? -1
  • The TTM is 19.250. Seems overpriced? -1
Trends
Current periodCompared to+/- 
EOD11.986MRQ10.441+1.545
MRQ10.441TTM19.250-8.809
TTM19.250YOY12.265+6.985
TTM19.2505Y12.119+7.131
5Y12.11910Y12.1190.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD11.9861.835+10.151
MRQ10.4412.006+8.435
TTM19.2502.774+16.476
YOY12.2653.453+8.812
5Y12.1192.713+9.406
10Y12.1192.402+9.717
2. Total Gains per Share

2.4. Latest News of Vivoryon Therapeutics NV

Does Vivoryon Therapeutics NV still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from Vivoryon Therapeutics NV to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2022-11-18
11:50
Following a 48% decline over last year, recent gains may please Vivoryon Therapeutics N.V. (AMS:VVY) institutional ownersRead
2022-11-01
12:36
Vivoryon Therapeutics (AMS:VVY) Is In A Good Position To Deliver On Growth PlansRead

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Vivoryon Therapeutics NV compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.012-100%-0.2220%0.068-100%0.068-100%
Book Value Growth---0.038-0.021-45%-0.306+702%-0.161+322%-0.161+322%
Book Value Per Share--0.7510.739+2%1.168-36%1.190-37%1.190-37%
Book Value Per Share Growth---0.016-100%-0.2580%-0.1180%-0.1180%
Current Ratio--7.0725.675+25%12.965-45%22.108-68%22.108-68%
Debt To Asset Ratio--0.3250.3260%0.160+103%0.196+66%0.196+66%
Debt To Equity Ratio--0.4810.4830%0.210+129%0.273+76%0.273+76%
Dividend Per Share----0%-0%-0%-0%
Eps---0.285-0.154-46%-0.236-17%-0.183-36%-0.183-36%
Eps Growth---0.091-100%-0.0950%-0.0390%-0.0390%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Net Profit Margin----0%-0%-0%-0%
Operating Margin----0%-0%-0%-0%
Operating Ratio----0%-0%-0%-0%
Pb Ratio11.986+13%10.44119.250-46%12.265-15%12.119-14%12.119-14%
Pe Ratio-31.543-15%-27.478-14.268-48%-48.242+76%-31.438+14%-31.438+14%
Price Per Share9.000+13%7.84014.140-45%11.764-33%10.618-26%10.618-26%
Profit Growth--3.82011.332-66%-6.050+258%-1.017+127%-1.017+127%
Quick Ratio--0.9450.639+48%0.125+654%4.923-81%4.923-81%
Return On Assets---0.257-0.135-47%-0.180-30%-0.136-47%-0.136-47%
Return On Equity---0.380-0.200-47%-0.226-41%-0.178-53%-0.178-53%
Total Gains Per Share---0.012-100%-0.2220%0.068-100%0.068-100%
Usd Book Value--17189477.40016907606.100+2%26730535.400-36%27232457.909-37%27232457.909-37%
Usd Book Value Change Per Share---0.013-100%-0.2310%0.071-100%0.071-100%
Usd Book Value Per Share--0.7800.767+2%1.212-36%1.235-37%1.235-37%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.296-0.160-46%-0.245-17%-0.190-36%-0.190-36%
Usd Price Per Share9.344+13%8.13914.680-45%12.213-33%11.023-26%11.023-26%
Usd Profit---6531835.300-3521314.850-46%-5391632.150-17%-4179038.145-36%-4179038.145-36%
Usd Revenue----0%-0%-0%-0%
Usd Total Gains Per Share---0.013-100%-0.2310%0.071-100%0.071-100%
 EOD+2 -2MRQTTM+10 -14YOY+5 -135Y+4 -1810Y+4 -18

3.2. Fundamental Score

Let's check the fundamental score of Vivoryon Therapeutics NV based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-31.543
Price to Book Ratio (EOD)Between0-111.986
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.945
Current Ratio (MRQ)Greater than17.072
Debt to Asset Ratio (MRQ)Less than10.325
Debt to Equity Ratio (MRQ)Less than10.481
Return on Equity (MRQ)Greater than0.15-0.380
Return on Assets (MRQ)Greater than0.05-0.257
Total3/10 (30.0%)

3.3. Technical Score

Let's check the technical score of Vivoryon Therapeutics NV based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5051.271
Ma 20Greater thanMa 508.887
Ma 50Greater thanMa 1008.705
Ma 100Greater thanMa 2008.204
OpenGreater thanClose9.200
Total4/5 (80.0%)



Latest Balance Sheet

Balance Sheet of 2022-06-30. Currency in EUR. All numbers in thousands.

Summary
 As reported
Total Liabilities -
Total Stockholder Equity+ -
Total Assets = -

Assets

Total Assets-
Total Current Assets30,990
Long-term Assets30,990
Total Current Assets
Net Receivables 4,141
Other Current Assets 2,231
Total Current Assets  (as reported)30,990
Total Current Assets  (calculated)6,372
+/- 24,618
Long-term Assets
Property Plant Equipment 227
Long-term Assets  (as reported)0
Long-term Assets  (calculated)227
+/- 227

Liabilities & Shareholders' Equity

Total Current Liabilities4,382
Long-term Liabilities-
Total Stockholder Equity-
Total Current Liabilities
Accounts payable 3,681
Other Current Liabilities 444
Total Current Liabilities  (as reported)4,382
Total Current Liabilities  (calculated)4,125
+/- 257
Long-term Liabilities
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)0
+/-0
Total Stockholder Equity
Common Stock22,050
Other Stockholders Equity 6,889
Total Stockholder Equity (as reported)0
Total Stockholder Equity (calculated)28,939
+/- 28,939
Other
Net Tangible Assets 24,725



Balance Sheet

Currency in EUR. All numbers in thousands.

 Trend2022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-30
> Total Assets 
0
45,861
0
37,900
0
29,751
0
23,041
0
24,520
0
0
0024,520023,041029,751037,900045,8610
   > Total Current Assets 
45,377
45,377
36,910
36,910
28,793
28,793
22,130
22,130
28,513
20,229
30,990
30,990
30,99030,99020,22928,51322,13022,13028,79328,79336,91036,91045,37745,377
       Cash And Cash Equivalents 
0
41,524
0
3,623
0
26,306
0
19,832
0
14,661
0
0
0014,661019,832026,30603,623041,5240
       Short-term Investments 
0
0
0
30,848
0
0
0
667
0
7
0
0
007066700030,848000
       Net Receivables 
602
602
114
114
129
129
474
474
0
3,360
4,141
4,141
4,1414,1413,3600474474129129114114602602
       Other Current Assets 
21
21
1,994
1,994
21
21
675
675
8,652
1,888
2,231
2,231
2,2312,2311,8888,65267567521211,9941,9942121
   > Long-term Assets 
0
484
0
989
0
958
0
910
0
4,291
0
0
004,29109100958098904840
       Property Plant Equipment 
465
465
422
422
390
390
343
343
315
285
227
227
227227285315343343390390422422465465
       Intangible Assets 
0
16
0
0
0
565
0
0
0
533
0
0
00533000565000160
       Other Assets 
0
0
1
1
3
3
15
15
14
3,473
14
14
14143,473141515331100
> Total Liabilities 
0
3,196
0
2,825
0
3,530
0
7,570
0
7,963
0
0
007,96307,57003,53002,82503,1960
   > Total Current Liabilities 
930
930
616
616
1,325
1,325
5,271
5,271
6,263
5,051
4,382
4,382
4,3824,3825,0516,2635,2715,2711,3251,325616616930930
       Accounts payable 
539
539
346
346
911
911
4,988
4,988
5,284
4,360
3,681
3,681
3,6813,6814,3605,2844,9884,988911911346346539539
       Other Current Liabilities 
62
62
131
131
147
147
192
192
887
366
444
444
4444443668871921921471471311316262
   > Long-term Liabilities 
0
2,266
0
2,209
0
2,205
0
2,299
0
2,912
0
0
002,91202,29902,20502,20902,2660
       Capital Lease Obligations Min Short Term Debt
0
406
0
360
0
314
0
270
0
224
0
0
0022402700314036004060
       Long-term Liabilities Other 
0
0
0
1
0
0
0
0
0
513
0
0
00513000001000
> Total Stockholder Equity
0
42,665
0
35,075
0
26,221
0
15,471
0
16,557
0
0
0016,557015,471026,221035,075042,6650
   Common Stock
19,975
19,975
19,975
19,975
19,975
19,975
19,975
19,975
20,020
20,050
22,050
22,050
22,05022,05020,05020,02019,97519,97519,97519,97519,97519,97519,97519,975
   Retained Earnings Total Equity000000000000
   Accumulated Other Comprehensive Income 000000000000
   Capital Surplus 000000000000
   Treasury Stock000000000000
   Other Stockholders Equity 
-562
-562
-582
-582
3,749
3,749
4,669
4,669
5,222
6,168
6,889
6,889
6,8896,8896,1685,2224,6694,6693,7493,749-582-582-562-562



Balance Sheet

Currency in EUR. All numbers in thousands.




Cash Flow

Currency in EUR. All numbers in thousands.




Income Statement

Currency in EUR. All numbers in thousands.


Latest Income Statement (annual, 2021-12-31)

Gross Profit (+$)
totalRevenue10,764
Cost of Revenue-1,569
Gross Profit9,1969,195
 
Operating Income (+$)
Gross Profit9,196
Operating Expense-23,663
Operating Income-12,898-14,467
 
Operating Expense (+$)
Research Development17,452
Selling General Administrative2,354
Selling And Marketing Expenses-
Operating Expense23,66319,806
 
Net Interest Income (+$)
Interest Income21
Interest Expense-24
Net Interest Income-3-3
 
Pretax Income (+$)
Operating Income-12,898
Net Interest Income-3
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-12,223-12,898
EBIT - interestExpense = -12,823
-12,223
-12,631
Interest Expense24
Earnings Before Interest and Taxes (ebit)-12,799-12,199
Earnings Before Interest and Taxes (ebitda)-12,034
 
After tax Income (+$)
Income Before Tax-12,223
Tax Provision-432
Net Income From Continuing Ops-12,655-12,655
Net Income-12,655
Net Income Applicable To Common Shares-12,655
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses7
Total Other Income/Expenses Net-3
 

Comments

Join the conversation.

Leave a comment

Stay informed with my latest content.

Subscribe to my newsletter and receive an email as soon as I add content to PenkeTrading.com.


By clicking Register, you agree to the General Terms and Conditions.
Penke's Market Notifications
ACEINTEG.NSE
3 minutes ago

I found you a RSI Bullish Hidden Divergence on the daily chart of ACEINTEG.NSE.

ACEINTEG.NSE Daily Candlestick Chart
ACEWIN.BSE
3 minutes ago

I found you a STOCH Bearish Hidden Divergence on the daily chart of ACEWIN.BSE.

ACEWIN.BSE Daily Candlestick Chart
ACAN.OTCQB
5 minutes ago

I found you a STOCH Bullish Reversal Divergence on the daily chart of ACAN.OTCQB.

ACAN.OTCQB Daily Candlestick Chart
4RUJ.XETRA
21 minutes ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of 4RUJ.XETRA.

4RUJ.XETRA Daily Candlestick Chart
1NBA.STU
33 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of 1NBA.STU.

1NBA.STU Daily Candlestick Chart
0Q6Q.LSE
57 minutes ago

I found you a Golden Cross on the daily chart of 0Q6Q.LSE.

0Q6Q.LSE Daily Candlestick Chart
0O9Q.LSE
57 minutes ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of 0O9Q.LSE.

0O9Q.LSE Daily Candlestick Chart
0NPT.LSE
59 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of 0NPT.LSE.

0NPT.LSE Daily Candlestick Chart
0MGE.LSE
1 hour ago

I found you a Golden Cross on the daily chart of 0MGE.LSE.

0MGE.LSE Daily Candlestick Chart
0I5O.LSE
1 hour ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of 0I5O.LSE.

0I5O.LSE Daily Candlestick Chart
APELY.PINK
2 hours ago

I found you a STOCH Bullish Hidden Divergence on the daily chart of APELY.PINK.

APELY.PINK Daily Candlestick Chart
IVZINNIFTY.NSE
2 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of IVZINNIFTY.NSE.

IVZINNIFTY.NSE Daily Candlestick Chart
FBT.NYSE ARC
2 hours ago

I found you a Golden Cross on the daily chart of FBT.NYSE ARC.

FBT.NYSE ARC Daily Candlestick Chart
EWW.NYSE ARC
2 hours ago

I found you a Golden Cross on the daily chart of EWW.NYSE ARC.

EWW.NYSE ARC Daily Candlestick Chart
SHRIKRISH.BSE
2 hours ago

I found you a Death Cross on the daily chart of SHRIKRISH.BSE.

SHRIKRISH.BSE Daily Candlestick Chart
BBH.NASDAQ
2 hours ago

I found you a Golden Cross on the daily chart of BBH.NASDAQ.

BBH.NASDAQ Daily Candlestick Chart
KCCA.NYSE ARC
2 hours ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of KCCA.NYSE ARC.

KCCA.NYSE ARC Daily Candlestick Chart
TUGN.NASDAQ
2 hours ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of TUGN.NASDAQ.

TUGN.NASDAQ Daily Candlestick Chart
JPST.BATS
2 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of JPST.BATS.

JPST.BATS Daily Candlestick Chart
SMDD.NYSE ARC
3 hours ago

I found you a Death Cross on the daily chart of SMDD.NYSE ARC.

SMDD.NYSE ARC Daily Candlestick Chart
PZA.NYSE ARC
3 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of PZA.NYSE ARC.

PZA.NYSE ARC Daily Candlestick Chart
PTLC.BATS
3 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of PTLC.BATS.

PTLC.BATS Daily Candlestick Chart
TENG.NYSE ARC
3 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of TENG.NYSE ARC.

TENG.NYSE ARC Daily Candlestick Chart
VBB.NASDAQ
3 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of VBB.NASDAQ.

VBB.NASDAQ Daily Candlestick Chart
SGTM.PINK
3 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of SGTM.PINK.

SGTM.PINK Daily Candlestick Chart